Literature DB >> 28066038

PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.

Eric J Sorscher1, Jeong S Hong1, William B Parker1.   

Abstract

Intratumoral expression of the E. coli purine nucleoside phosphorylase (PNP) gene was originally described by our laboratories as a means to inhibit growth of solid tumors in vivo. The approach generates purine bases that disrupt DNA, RNA, and protein synthesis, a unique mechanism when compared with all approved or experimental cancer therapeutics. Use of PNP has been validated by numerous laboratories worldwide against human tumor xenografts (lung, liver, pancreas, bladder, glioma, and prostate, among others). Data from a recently completed phase 1 clinical trial has indicated substantial anti-cancer activity in human subjects with no serious toxicities.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28066038      PMCID： PMC5216485     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN： 0065-7778


  35 in total

1.  Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.

Authors:  L Mohr; S Shankara; S K Yoon; T U Krohne; M Geissler; B Roberts; H E Blum; J R Wands
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy.

Authors:  M Puhlmann; M Gnant; C K Brown; H R Alexander; D L Bartlett
Journal:  Hum Gene Ther       Date:  1999-03-01       Impact factor: 5.695

3.  Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase.

Authors:  B W Hughes; S A King; P W Allan; W B Parker; E J Sorscher
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

4.  Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.

Authors:  D Voeks; R Martiniello-Wilks; V Madden; K Smith; E Bennetts; G W Both; P J Russell
Journal:  Gene Ther       Date:  2002-06       Impact factor: 5.250

5.  Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine.

Authors:  Sophie Deharvengt; Soukaina Rejiba; Séverine Wack; Marc Aprahamian; Amor Hajri
Journal:  Int J Oncol       Date:  2007-06       Impact factor: 5.650

6.  Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.

Authors:  Rosetta Martiniello-Wilks; Allison Dane; Dale J Voeks; Geetha Jeyakumar; Elin Mortensen; Jan M Shaw; Xiao Yang Wang; Gerald W Both; Pamela J Russell
Journal:  J Gene Med       Date:  2004-01       Impact factor: 4.565

7.  Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.

Authors:  G Fontanini; R Pingitore; D Bigini; S Vignati; S Pepe; A Ruggiero; P Macchiarini
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

8.  Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G1 phase restriction point block.

Authors:  D L Tay; P S Bhathal; R M Fox
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Authors:  E L Rosenthal; T K Chung; W B Parker; P W Allan; L Clemons; D Lowman; J Hong; F R Hunt; J Richman; R M Conry; K Mannion; W R Carroll; L Nabell; E J Sorscher
Journal:  Ann Oncol       Date:  2015-04-21       Impact factor: 32.976

10.  Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

Authors:  W B Parker; P W Allan; W R Waud; J S Hong; E J Sorscher
Journal:  Cancer Gene Ther       Date:  2011-03-11       Impact factor: 5.987
View more
  2 in total

Review 1.  Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.

Authors:  Turang E Behbahani; Eben L Rosenthal; William B Parker; Eric J Sorscher
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

2.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.